Live Breaking News & Updates on Nirali shah

Stay informed with the latest breaking news from Nirali shah on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Nirali shah and stay connected to the pulse of your community

Crafted in Indian labs, NexCAR19 takes India to next level in cancer care

Crafted in Indian labs, NexCAR19 takes India to next level in cancer care
thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.

India , Maryland , United-states , Bombay , Maharashtra , Hyderabad , Andhra-pradesh , National-institutes-of-health , Mumbai , American , Hasmukh-jain , Alka-dwivedi

Crafted in Indian labs, NexCAR19 takes India to next level in cancer care

Crafted in Indian labs, NexCAR19 takes India to next level in cancer care
thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.

India , United-states , Maryland , Bombay , Maharashtra , Mumbai , American , Atharva-karulkar , Gaurav-narula , Rahul-purwar , Nirali-shah , Shirish-arya

MNCs look towards India for a booster dose

In recent months, several pharma multinational corporations (MNCs) are increasingly turning to Indian companies to expand market reach in the country's pharmaceuticals sector.

Sanofi's partnerships with Dr Reddy's, Cipla, and Emcure, AstraZeneca and Mankind Pharma - teaming up for asthma medication distribution - are a few instances of this trend.

This strategy allows MNCs to leverage established Indian networks and reach a wider audience. Indian companies also benefit from global brands and expertise, say analysts.

China , United-states , India , Russia , America , Kunal-shah , Kinjal-shah , Nirali-shah , Uttam-ghosh-rediff , Ashika-group , Astrazeneca , Emcure-pharmaceuticals

India's First Homegrown CAR T-Cell Therapy to Treat Leukemia

From curiosity to groundbreaking cure: How a team in India developed a game-changing cancer therapy. You won't believe the results!

National-institutes-of-health , Maryland , United-states , India , Mumbai , Maharashtra , Bombay , American , Nirali-shah , Alka-dwivedi , Rahul-purwar , Gaurav-narula

Revised Schedule M elicits mixed response

A notification of the revised Schedule M rules by the Ministry of Health and Family Welfare has elicited mixed responses from the pharma sector and industry observers.

While the industry has welcomed the revision of rules, several analysts said that implementation and compliance can become a challenge for smaller pharmaceutical companies.

The Schedule M of the Drugs and Cosmetics Rules specifies the good manufacturing practices (GMPs), which aim to ensure quality of drugs made in the country.

India , Nirali-shah , Entod-pharma , Nikkhilk-masurkar , Ministry-of-health , Ashika-group , World-health-organisation , Family-welfare , Cosmetics-rules , Central-drug-standards , Control-organisation , Business-news

Dubai's gold business is heading towards a defining moment – and it is not just one reason only

What Dubai does not require is being selectively targeted by some global entities

Russia , Ukraine , India , Venezuela , Brazil , Switzerland , London , City-of , United-kingdom , Dubai , Dubayy , United-arab-emirates

Brainstorm's ALS Data Fail to Persuade FDA Advisors, Who Vote Down the Stem Cell Therapy

NurOwn, Brainstorm Cell Therapeutics’ experimental stem cell therapy for ALS, did not win the backing of an independent panel of FDA advisors. Many advisory committee members said they want to see more data from another clinical trial, the same guidance the FDA has given the biotech for nearly three years.

Kathleen-osullivan-fortin , Peter-marks , Nirali-shah , Andrew-buckley , Caleb-alexander , Mark-tuszynski , National-cancer-institute , Harvard-medical-school , Translational-neuroscience-institute , University-of-california-san-diego , Buckley , Cell-therapeutics

FDA Panel Overwhelmingly Rejects ALS Cell Therapy

Echoing concerns from agency reviewers, advisors can't find evidence of efficacy

Maryland , United-states , Bethesda , Massachusetts , G-caleb-alexander , Lisa-lee , Gumei-liu , Kathleen-osullivan-fortin , Nirali-shah , Judy-george , National-cancer-institute-in-bethesda , Johns-hopkins-university-in-baltimore

Nirali Shah (pictured) has been promoted from partner to head of US D&O

London , City-of , United-kingdom , New-york , United-states , Nirali-shah , John-lloyd , Alyssa-gerardi , Daisy-jackson , Karl-hennessy , Hennessy , Global-risk-solutions

People Moves: DUAL North America Named Gosselink EVP Fine Art; Hennessy Now CEO McGill Global Risk Solutions

DUAL North America appointed of Peter Gosselink as executive vice president of its fine art program. Gosselink trained as a marine underwriter

New-york , United-states , Tokio , Tokyo , Japan , London , City-of , United-kingdom , America , Peter-gosselink , Nirali-shah , Alyssa-gerardi